Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Letter Commentary & Co-Mentions | Period / Date | Action |
|---|---|---|---|
“Tarsus Pharmaceuticals, a commercial-stage company focused on eye care, declined -10% despite continued commercial progress for its demodex blepharitis treatment, XDEMVY. While actual script...” | Q2 2026 Jul 28, 2026 | Preview | |
“RTW Biotech delivered -4.6% in 2024 but achieved 86% five-year returns, outperforming biotech indices. The fund focuses...” | Q4 2024 Dec 31, 2024 | Preview |
Read unredacted commentary excerpts, portfolio weight disclosures, and high-conviction theses from hedge fund managers discussing $TARS.(6 additional institutional mentions locked).
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.